[go: up one dir, main page]

WO2000065067A3 - Prostate-specific polynucleotides, polypeptides and their methods of use - Google Patents

Prostate-specific polynucleotides, polypeptides and their methods of use Download PDF

Info

Publication number
WO2000065067A3
WO2000065067A3 PCT/US2000/010920 US0010920W WO0065067A3 WO 2000065067 A3 WO2000065067 A3 WO 2000065067A3 US 0010920 W US0010920 W US 0010920W WO 0065067 A3 WO0065067 A3 WO 0065067A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate
androgen
specific
regulated
neoplastic condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/010920
Other languages
French (fr)
Other versions
WO2000065067A2 (en
Inventor
Peter S Nelson
Leroy Hood
Biaoyang Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Priority to AU44844/00A priority Critical patent/AU4484400A/en
Publication of WO2000065067A2 publication Critical patent/WO2000065067A2/en
Publication of WO2000065067A3 publication Critical patent/WO2000065067A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides isolated polynucleotides encoding prostate-specific, androgen-regulated polypeptides. The invention also provides substantially pure polynucleotides corresponding to genomic regulator regions of prostate-specific, androgen-regulated polynucleotides. Fragments and probes of polynucleotides thereof are also provided. The invention further provides a method of diagnosing or predicting the susceptibility of a prostate neoplastic condition in an individual suspected of having a neoplastic condition of the prostate. The method consists of: (a) obtaining a fluid or prostate sample of the individual; (b) determining the expression level of the prostate-specific, androgen-regulated polynucleotide or polypeptide, and (c) comparing the expression levels of the prostate-specific, androgen-regulated polynucleotide or polypeptide to expression levels from a normal fluid sample, from normal prostate cells or from an androgen-dependent cell line, wherein a two-fold change in expression level of the prostate-specific, androgen-regulated polynucleotide or polypeptide in the individual fluid or prostate sample as compared to the normal fluid or normal prostate cells or an androgen-dependent cell line indicates the presence of a prostate neoplastic condition. Methods of identifying compounds that selectively inhibit or increase prostate-specific polypeptides of the invention and a method of treating or reducing the progression of a prostate neoplastic condition are also provided.
PCT/US2000/010920 1999-04-23 2000-04-21 Prostate-specific polynucleotides, polypeptides and their methods of use Ceased WO2000065067A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44844/00A AU4484400A (en) 1999-04-23 2000-04-21 Prostate-specific polynucleotides, polypeptides and their methods of use

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US13077899P 1999-04-23 1999-04-23
US60/130,778 1999-04-23
US15158599P 1999-08-30 1999-08-30
US60/151,585 1999-08-30
US17400399P 1999-12-30 1999-12-30
US60/174,003 1999-12-30
US17775100P 2000-01-24 2000-01-24
US60/177,751 2000-01-24

Publications (2)

Publication Number Publication Date
WO2000065067A2 WO2000065067A2 (en) 2000-11-02
WO2000065067A3 true WO2000065067A3 (en) 2001-08-02

Family

ID=27494878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010920 Ceased WO2000065067A2 (en) 1999-04-23 2000-04-21 Prostate-specific polynucleotides, polypeptides and their methods of use

Country Status (2)

Country Link
AU (1) AU4484400A (en)
WO (1) WO2000065067A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6551778B1 (en) 1999-01-28 2003-04-22 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
AU2001274981A1 (en) * 2000-05-25 2001-12-03 Incyte Genomics, Inc. Drug metabolizing enzymes
BR0115728A (en) * 2000-11-28 2003-09-23 Wyeth Corp Analysis of expression of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer.
US7393921B2 (en) 2000-12-04 2008-07-01 Institute For Systems Biology Prostate-specific polypeptide pamp and encoding nucleic acid molecules
WO2002081518A2 (en) * 2001-02-21 2002-10-17 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
US7071303B2 (en) 2001-03-28 2006-07-04 Institute For Systems Biology Androgen regulated prostate specific nucleic acids
CN101724071A (en) 2004-10-08 2010-06-09 杜门蒂斯有限公司 Single domain antibodies against TNFRl and methods of use therefor
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
FR2890859B1 (en) * 2005-09-21 2012-12-21 Oreal DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022360A1 (en) * 1995-01-20 1996-07-25 Human Genome Sciences, Inc. Human prostatic specific reductase
WO1999003990A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. 64 human secreted proteins
WO1999033982A2 (en) * 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i
DE19813839A1 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences and protein products from tumor breast tissue, useful for breast cancer therapy
WO1999062942A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO2000000605A1 (en) * 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2000012758A1 (en) * 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
WO2000018961A2 (en) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000029448A2 (en) * 1998-11-17 2000-05-25 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022360A1 (en) * 1995-01-20 1996-07-25 Human Genome Sciences, Inc. Human prostatic specific reductase
WO1999003990A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. 64 human secreted proteins
WO1999033982A2 (en) * 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i
DE19813839A1 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences and protein products from tumor breast tissue, useful for breast cancer therapy
WO1999062942A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO2000000605A1 (en) * 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2000012758A1 (en) * 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
WO2000018961A2 (en) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000029448A2 (en) * 1998-11-17 2000-05-25 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
C-H. LAI ET AL.: "Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics.", GENOME RESEARCH, vol. 10, no. 5, 2000, pages 703 - 713, XP000929862 *
DATABASE EBI 11 July 1997 (1997-07-11), L. HILLIER ET AL.: "Accession number AA454187", XP002147801 *
DATABASE EBI 26 August 1996 (1996-08-26), L. HILLIER ET AL.: "Accession number AA035790", XP002147800 *
DATABASE EBI 4 June 1997 (1997-06-04), L. HILLIER ET AL.: "Accession no. AA442517", XP002147799 *
DATABASE EMBL 5 February 1999 (1999-02-05), NATIONAL CANER INSTITUTE: "Homo sapiens cDNA clone", XP002158124 *
DATABASE EMBL 5 May 1997 (1997-05-05), L. HILLIER ET AL.: "WashU-Merck EST Project 1997", XP002158122 *
DATABASE EMBL 9 September 1998 (1998-09-09), W. KIMMERLY ET AL.: "Sequencing of human chromosome 21.", XP002158123 *
LIN B ET AL: "PART-1: A NOVEL HUMAN PROSTATE-SPECIFIC, ANDROGEN-REGULATED GENE THAT MAPS TO CHROMOSOME 5Q12", CANCER RESEARCH,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD,US, vol. 60, no. 4, 15 February 2000 (2000-02-15), pages 858 - 863, XP000929855, ISSN: 0008-5472 *
LIN B ET AL: "PROSTATE-LOCALIZED AND ANDROGEN-REGULATED EXPRESSION OF THE MEMBRANE-BOUND SERINE PROTEASE TMPRSS2", CANCER RESEARCH,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD,US, vol. 59, 1 September 1999 (1999-09-01), pages 4180 - 4184, XP000929801, ISSN: 0008-5472 *
M.A. VAN DIJK ET AL.: "Pbx1 is converted into a trascriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia.", PROC. NATL. ACAD. SCI. USA, vol. 90, July 1993 (1993-07-01), pages 6061 - 6065, XP000978872 *
P.J. ROCHE ET AL.: "A consensus DNA-binding site for the androgen-receptor.", MOLECULAR ENDOCRINOLOGY, vol. 6, no. 12, December 1992 (1992-12-01), pages 2229 - 2235, XP000934123 *
PAOLONI-GIACOBINO A ET AL: "CLONING OF THE TMPRSS2 GENE, WHICH ENCODES A NOVEL SERINE PROTEASE WITH TRANSMEMBRANE, LDLRA, AND SRCR DOMAINS AND MAPS TO 21Q22.3", GENOMICS,US,ACADEMIC PRESS, SAN DIEGO, vol. 44, no. 3, 15 September 1997 (1997-09-15), pages 309 - 320, XP000856785, ISSN: 0888-7543 *
V. HAWKINS ET AL.: "PEDB: the Prostate expression database.", NUCLEIC ACIDS RESEARCH, vol. 27, no. 1, 1999, pages 204 - 208, XP000933960 *
Z- SUN ET AL.: "Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 gene.", NUCLEIC ACIDS RESEARCH, vol. 25, no. 16, 1997, pages 3318 - 3325, XP002147416 *

Also Published As

Publication number Publication date
WO2000065067A2 (en) 2000-11-02
AU4484400A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
WO2000065067A3 (en) Prostate-specific polynucleotides, polypeptides and their methods of use
ES2925983T3 (en) Method for using gene expression to determine prostate cancer prognosis
WO2002061128A3 (en) Method of determining a chemotherapeutic regimen based on ercc1 expression
WO2002103031A3 (en) Methods for detecting and treating the early onset of aging-related conditions
WO2000004187A3 (en) Methods and kits for diagnosing and determination of the predisposition of diseases
WO2000024933A8 (en) Detection of loss of heterozygosity in tumor and serum of melanoma patients
WO1997036535A3 (en) Biomarkers for detection, diagnosis and prognosis of prostate cancer
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
EP2154245A3 (en) Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
ATE224456T1 (en) DETECTION OF A GENETIC PREDISPOSITION FOR DIABETIC RETINOPATHY WITH THE RISK OF VISION LOSS
WO2004056874A3 (en) Neuropilin-1 inhibitors
WO2004075713A3 (en) Multiple marker assay for detection of ovarian cancer
WO1997017469A9 (en) Method of predicting the risk of prostate cancer morbidity and mortality
WO2001075175A3 (en) Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
WO2004077060A3 (en) Assay for detection of renal cell carcinoma
WO2003021229A3 (en) Diagnostic and prognostic tests
Young et al. New stool screening tests for colorectal cancer
WO2003072828A3 (en) Fcgammariib polymorphisms detection in system lupus erythematosus
WO2000005374A3 (en) Molecules associated with cell proliferation
KR20190035677A (en) Detection of colorectal adenoma and carcinoma, setting and monitoring of colon
ATE292176T1 (en) NUCLEIC ACID MOLECULES THAT CORRELATE WITH THE WEAK RHESUS-D PHENOTYPE
WO1998026097A3 (en) NUCLEIC ACID PRIMERS AND PROBES FOR DETECTING $i(LEGIONELLA PNEUMOPHILA)
ATE285108T1 (en) ADAPTIVE AND SELECTIVE LEVEL CONDITIONING OF A READING CHANNEL IN STORAGE TECHNOLOGIES
Cao et al. BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China
WO1995017524A3 (en) Automatic genotype determination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10019348

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP